Report

Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)

See allHide authors and affiliations

Science  27 Nov 1998:
Vol. 282, Issue 5394, pp. 1714-1717
DOI: 10.1126/science.282.5394.1714

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Fas ligand (CD95L) inhibits T cell function in immune-privileged organs such as the eye and testis, yet in most tissues CD95L expression induces potent inflammatory responses. With a stably transfected colon carcinoma cell line, CT26-CD95L, the molecular basis for these divergent responses was defined. When injected subcutaneously, rejection of CT26-CD95L was caused by neutrophils activated by CD95L. CT26-CD95L survived in the intraocular space because of the presence of transforming growth factor–β (TGF-β), which inhibited neutrophil activation. Providing TGF-β to subcutaneous sites protected against tumor rejection. Thus, these cytokines together generate a microenvironment that promotes immunologic tolerance, which may aid in the amelioration of allograft rejection.

  • * To whom correspondence should be addressed. E-mail: gnabel{at}umich.edu

View Full Text